Psoriasis

Achievement of ≥75 percent reduction in Psoriasis Area and Severity Index lower in both current, former smokers Tobacco smoking is negatively associated with resolution of psoriasis symptoms, according to a study published in the April issue of Tobacco Induced Diseases. Yan Qiang, from the School of Medicine at Tongji University in Shanghai, and colleagues explored the...

A preliminary clinical trial suggests that topical rosuvastatin or melatonin are effective at controlling psoriatic skin rashes, with significant benefits reported on days 30 and 60. Psoriasis, a chronic inflammatory skin disorder affecting about 3% of the population, typically manifests in adolescence or later adulthood. The most common form is chronic plaque psoriasis, characterized by...

A new clinical study shows that tildrakizumab effectively improves the quality of life and enhances the work productivity of those living with psoriasis. Psoriasis is a prevalent chronic inflammatory disorder affecting about 3% of US individuals aged 20 and older, making it a significant immune-mediated disease in the US. The economic burden of psoriasis is...

An updated review highlights the role of dysregulated adipokines in cardiovascular comorbidities in psoriasis and finds that biologics exert a cardioprotective role in some cases. Psoriasis is a prevalent chronic, inflammatory, multi-organ, systemic disease affecting millions worldwide. Its most common form, plaque psoriasis, manifests as erythematous plaques with silvery scales, notably on the elbows, knees,...

Investigator Global Assessment of 0 or 1 occurred in significantly more patients receiving tacrolimus microemulsion versus placebo For scalp psoriasis, 0.1 percent tacrolimus microemulsion has good efficacy and safety, according to a study published online Feb. 12 in Dermatology and Therapy. Andreas Pinter, M.D., from the University Hospital Frankfurt in Germany, and colleagues conducted a multicenter,...

Treatment with bimekizumab for patients with moderate-to-severe plaque psoriasis showed significant positive results and clinical outcomes in a phase 3 study. Plaque psoriasis is a chronic inflammatory illness mediated by the immune system. It causes large skin lesions that can be scaly, thick, and, at times, pruritic. This substantial illness burden influences patients’ quality of...

A review of clinical trials finds deucravacitinib to be an effective and safe treatment for moderate-to-severe psoriasis. Psoriasis is a chronic inflammatory skin disease with an estimated prevalence of 2–3% globally. Systemic therapies are often required for moderate-to-severe disease; however, conventional systemic therapies have numerous disadvantages or limitations.  A literature review published in the Journal...

There are many positive developments in psoriasis treatment. Novel biologics such as interleukin 23 inhibitors and small molecule inhibitors provide improved effectiveness and a wider range of choices. Progress in topical treatments utilizing microneedles and nanoparticles enhances drug delivery, while personalized medicine directed by biomarkers offers the possibility of customized therapy and improved results.  Psoriasis...

A recent retrospective analysis reveals that ixekizumab-induced urticaria in psoriasis patients is associated with a shorter duration of remission, suggesting a role of mast cell activation in this process. The findings emphasize the need for targeted management strategies for patients exhibiting these adverse reactions. Ixekizumab treatment in psoriasis patients may lead to urticaria and early...